Evidence map›Paper›PMID 40590904›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

[

Alberto Signore, Filippo Galli, Michela Varani, Giuseppe Campagna, Valeria Bentivoglio, Antonella Accardo, Giancarlo Morelli, Chiara Lauri

Abstract readClinical Trial, Phase I
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alberto SignoreNuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, "Sapienza" University, Rome, Italy. alberto.signore@uniroma1.it.ORCID 0000-0001-8923-648X
Filippo GalliNuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, "Sapienza" University, Rome, Italy.ORCID 0000-0002-3439-6010
Michela VaraniNuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, "Sapienza" University, Rome, Italy.ORCID 0000-0002-7766-9031
Giuseppe CampagnaNuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, "Sapienza" University, Rome, Italy.ORCID 0000-0002-1884-9171
Valeria BentivoglioNuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, "Sapienza" University, Rome, Italy.ORCID 0000-0003-4369-2281
Antonella AccardoDepartment of Pharmacy, University of Napoli "Federico II", Naples, Italy.ORCID 0000-0002-7899-2359
Giancarlo MorelliDepartment of Pharmacy, University of Napoli "Federico II", Naples, Italy.ORCID 0000-0002-5791-3690
Chiara LauriNuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, "Sapienza" University, Rome, Italy.ORCID 0000-0002-0314-5059

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aimed to develop a ready-to-use kit for

methodsHuman recombinant IL2 (hrIL2) and Aldesleukin (desIL2), conjugated with two different chelators (NODAGA and THP) were compared. Conjugated-IL2 was stored, freeze-dried at -80 °C and radiolabelled at room temperature. In vitro quality controls (iTLC, HPLC, SDS-PAGE, spectrometry and binding assays on activated T-lymphocytes) and in vivo biodistribution studies in BALB/c mice, were performed. The shelf life of the lyophilized kits was assessed up to 6 months of storage, by iTLC, HPLC and SDS-PAGE. First-in-human study was conducted in 5 volunteers by performing [

resultsMass spectrometry showed that only one molecule of THP or NODAGA is bound to N-terminus of both IL2 proteins. The most efficient conjugation was observed for THP-desIL2. [

conclusionsWe developed an efficient lyophilized kit of THP-desIL2 for

Indexed as

Gallium RadioisotopesInterleukin-2Lymphocyte ActivationPositron Emission Tomography Computed TomographyT-LymphocytesAdultAnimalsFemaleHealthy VolunteersHeterocyclic Compounds, 1-RingHumansMaleMiceMice, Inbred BALB CRadiopharmaceuticalsTissue DistributionGallium-68Gallium RadioisotopesHeterocyclic Compounds, 1-RingInterleukin-2Radiopharmaceuticals[68Ga]Ga-IL2BiodistributionHuman studyPET/CTT-lymphocytes

Identifiers

PMID40590904
PMCPMC12660392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.